Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708897 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
A Phase 1 study of CLL (Chronic Lymphocytic Leukemia) and SLL (Small Lymphocytic Lymphoma), sponsored by Lomond Therapeutics Holdings.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT06708897 is a Phase 1 study of CLL (Chronic Lymphocytic Leukemia) and SLL (Small Lymphocytic Lymphoma) that is actively recruiting participants, run by Lomond Therapeutics Holdings. The registered enrollment target is 66 participants, below the 300-participant average among 5 other CLL (Chronic Lymphocytic Leukemia) trials with a reported enrollment target (78% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06708897, a Phase 1 study of CLL (Chronic Lymphocytic Leukemia) and SLL (Small Lymphocytic Lymphoma), is actively recruiting participants, sponsored by Lomond Therapeutics Holdings.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
Conditions Studied
Interventions
- DRUG ZE 50-0134
Study Locations (4)
Ohio
- University of Cincinnati - Cincinnati
- The Ohio State University - Columbus
Kentucky
- Norton Cancer Institute, St. Matthews Campus - Louisville
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06708897
The ClinicalTrials.gov registry entry for NCT06708897 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 5 other CLL (Chronic Lymphocytic Leukemia) trials with a reported enrollment target (78% lower). The listed sponsor is Lomond Therapeutics Holdings, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with CLL (Chronic Lymphocytic Leukemia) appearing as the primary indexed condition, and to 1 intervention - of which ZE 50-0134 is the first listed.
NCT06708897 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Kentucky, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06708897 about?
NCT06708897 is a clinical study titled "A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas". This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
What is the current status of trial NCT06708897?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2025-04-08. Estimated completion is 2028-04.
What conditions does trial NCT06708897 study?
This clinical trial studies the following conditions: CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), CLL / SLL.
What interventions are being tested in trial NCT06708897?
The interventions under investigation include: ZE 50-0134 (DRUG).
Who is sponsoring clinical trial NCT06708897?
This trial is sponsored by Lomond Therapeutics Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708897 being conducted?
This trial has 4 study locations across Kentucky, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CLL (Chronic Lymphocytic Leukemia)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
RECRUITING · Phase 1
-
Improving Blood Stem Cell Collection and Transplant Procedures
COMPLETED · Phase 1
-
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RECRUITING
-
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
CLL (Chronic Lymphocytic Leukemia)
All registered trials for this condition
SLL (Small Lymphocytic Lymphoma)
All registered trials for this condition
Kentucky
All trials with a study site in Kentucky
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.